allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes

A preparation of allogeneic Epstein-Barr virus (EBV) specific cytotoxic T lymphocytes (CTL) with potential antineoplastic activity. Upon administration, the allogeneic EBV-specific CTLs are either harvested from a donor with an EBV-positive tumor or are donor CTLs activated against EBV-specific antigens ex vivo. Administration into a patient exerts a CTL response against EBV-positive tumor cells or EBV-infected cells. This results in cell lysis and inhibition of cancer cell proliferation. EBV, a ubiquitous human herpes virus, is associated with various malignancies, including nasopharyngeal carcinoma, Hodgkin disease, non-Hodgkin lymphoma, and other lymphomas.